Registration has been granted in the Republic of Belarus for Artlegia (olokizumab), the pioneering Russian drug for rheumatoid arthritis developed by R-Pharm. Artlegia has already completed registration in several countries, including Russia, Kazakhstan, Kyrgyzstan, and Azerbaijan, in addition to the Republic of Belarus. Furthermore, Artlegia has plans to register in several other countries.
Artlegia is the world’s first and only registered monoclonal antibody for the treatment of rheumatoid arthritis that blocks the cytokine IL-6, but not its receptor. A comprehensive program of international clinical trials, involving 2444 patients from 19 countries, unequivocally validated the efficacy and safety of “Artlegia” as a treatment for rheumatoid arthritis. Olokizumab has been recognized as a vital and essential medication in Russia, making it an indispensable option for medical treatment. Not only has it been included in the clinical guidelines for “Rheumatoid Arthritis,” but it has also earned a position in the provisional guidelines for treating, preventing, and diagnosing COVID-19.